Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

NCT04404023 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: UB-221

Sponsor

UBP Greater China (Shanghai) Co., Ltd